Simulated driving performance in healthy adults after night-time administration of 20  mg tasimelteon - Torres R, Fisher M, Birznieks G, Polymeropoulos C, Kay GG, Xiao C, Polymeropoulos MH.

An impairment in next day driving performance has been reported for almost every drug currently United States Food and Drug Administration (FDA) approved for improvement of sleep in chronic and transient insomnia. Tasimelteon, a melatonin receptor agonist,...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news